<DOC>
	<DOCNO>NCT00416884</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , total-body irradiation ( TBI ) donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) treat laboratory transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine alemtuzumab , remove T lymphocyte cell ( T cell ) donor cell transplant , may stop happen . PURPOSE : This clinical trial study well give fludarabine , alemtuzumab , total-body irradiation together donor stem cell transplant donor white blood cell ( WBC ) infusion work treat patient chronic phase chronic myelogenous leukemia ( CML ) respond previous imatinib mesylate .</brief_summary>
	<brief_title>Flu , Alemtuzumab , TBI Followed By Donor Stem Cell Chronic Phase CML</brief_title>
	<detailed_description>OBJECTIVES : - Determine treatment-related mortality patient imatinib mesylate-resistant chronic phase chronic myelogenous leukemia treat nonmyeloablative conditioning comprise fludarabine , alemtuzumab , total-body irradiation follow T-cell-depleted allogeneic stem cell transplantation post-transplantation allogeneic T-cell infusion . - Determine donor engraftment safely establish use partial T-cell depletion additional T-cell infusion patient . OUTLINE : Patients receive alemtuzumab IV 5-6 hour day -8 fludarabine IV day -4 -2 . Patients undergo total-body irradiation follow T-cell-depleted ( CD34+ select ) allogeneic stem cell transplantation day 0 . Patients receive allogeneic T-cell infusion day 30 60 . Patients also receive cyclosporine twice daily begin day -3 continue day 100 follow taper day 177 . PROJECTED ACCRUAL : Not specify .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion criterion : Patients age 475 chronic myelogenous leukemia ( CML ) treatable allogeneic hematopoietic stem cell transplant . Patients cytogenetically confirm chronic phase CML . Hematologic parameter chronic phase : ) Percentage blast peripheral blood marrow &lt; 15 % ii ) Percentage blast + promyelocytes peripheral blood bone marrow &lt; 30 % iii ) Percentage basophil blood marrow &lt; 20 % iv ) Platelet count &gt; 100 x 109/l Patients must demonstrate refractoriness/resistance STI571 define follow : ) Hematologically resistant failure achieve complete hematologic remission ( CHR ) despite 3 month STI571 therapy . ii ) Hematologically refractory rise WBC count &gt; 20 x 109/l confirm two sample take two week apart patient previous CHR despite concurrent treatment STI571 iii ) Cytogenetically resistant bone marrow cytogenetics show &gt; 65 % Philadelphia chromosome positivity ( Ph+ ) 6 month STI571 base therapy . iv ) Cytogenetically refractory An increase number Philadelphia chromosome positive ( Ph+ ) bone marrow cell least 30 % , increase &gt; 65 % , confirm sample least 1 month apart follow previous STI571 induce cytogenetic response , continue STI571 therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patients human leukocyte antigen ( HLA ) match sibling donor HLAA , B , DR locus . Patients unrelated hematopoietic stem cell donor must match use high resolution type class II human leukocyte antigen ( HLADR beta1 , 3 , 4 , 5 DQ beta1 ) match intermediate high resolution molecular type class I human leukocyte antigen ( HLAA , B , C ) locus . Patients accelerate blast crisis CML return chronic phase describe eligible . Written inform , voluntary consent . Exclusion criterion : Patients receive another investigational drug within 30 day . Fertile men unwilling use contraceptive technique 24 month follow treatment . Females pregnant fertile woman unwilling use contraceptive technique two month prior enter study 24 month follow treatment . Patients active bacterial fungal infection unresponsive medical therapy . Patients organ dysfunction include cardiac ejection fraction le 35 % pulmonary status diffuse capacity lung carbon monoxide ( DLCO ) less 40 % and/or receive supplemental oxygen . Liver Function Abnormalities : patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , varix , history bleeding varix , hepatic encephalopathy chronic viral hepatitis total serum bilirubin great 3 mg per deciliter symptomatic biliary disease . Patients history noncompliance medical regimen consider potentially unreliable . Patients history prior bone marrow peripheral blood stem cell transplantation . Patients serious , uncontrolled , concomitant medical condition HIV positive patient Eligibility criterion donor : Inclusion Criteria Donors : Sibling donor permit matched class I human leukocyte antigen ( HLAA , B ) , class II human leukocyte antigen ( DR ) locus . Unrelated donor must match class II human leukocyte antigen ( HLADR beta1,2,3,4,5 ) class II human leukocyte antigen ( DQ beta1 ) high resolution type intermediate resolution molecular type class I human leukocyte antigen ( HLAA , B , C ) locus . Donors must eligible serve peripheral stem cell allograft donor . Bone marrow donor permit protocol . Donors must &gt; 18 &lt; 75 year age . Exclusions Criteria Donors : Volunteer donor wish serve bone marrow donor refuse exogenous cytokine . Donors Human immunodeficiency virus ( HIV+ ) , Human Tlymphotropic virus ( HTLV1+ ) , hepatitis Bs Ag+.. Donors medical condition would result increase risk Granulocyte colonystimulating factor ( GCSF ) mobilization harvest peripheral blood stem cell ( PBSC ) include renal insufficiency Cr &gt; 2.0 , idiopathic splenomegaly , underlie coagulopathy , uncontrolled coronary artery disease , major surgery within 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>